Fig. 3

Benefits from extension to low-risk 2–16-year-old children. Benefits (in terms of non-death and death-associated Quality-Adjusted Life Days per year and per person of that age and risk group) gained from extension of vaccination to low-risk 2–16-year-old children. The benefit is given for each age and risk group (pink bars low risk, blue bars high risk). Note the change of scale in the last panel